New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast CancerDiagnostic criteriaPathologyWHO classificationBreast CancerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, ...
EP: 12.Treatment Options for HER2+, ER+ Metastatic Breast Cancer EP: 13.Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer Vijayakrishna Gadi, MD, PhD: I’m going to go with that a little further. So Nancy, when you think about hormone-positive, HER2-positive disease, so maybe...
[3]Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Rep Med. 2024;5(6):101575. [4]Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOP...
HER2-directed therapy: current treatment options for HER2-positive breast cancer Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin... S Ahmed,A Sami,J Xiang - 《Breast Cancer》 被引量: 74...
在中国,乳腺癌已成为女性恶性肿瘤中的头号杀手,而超过 90% 的女性在首次诊断时处于疾病早期 [1] 。在早期乳腺癌患者中,HR+/HER2-型占据了绝大多数。在早期 HR+/HER2-乳腺癌的治疗中,辅助内分泌治疗已经显著改善了患者的预后,并提高了他们的生存率。尽管取得了这样的进展,大约 20% 至 30% 的早期乳腺癌患者...
2. Saini KS, et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 2011;20(Suppl 3):S20–7. 3. Capelan M, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82. ...
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer. Sara A. Hurvitz, MD The year 2020 saw a myriad of promising studies that resulted in several FDA-approved options for patients wit...
受体酪氨酸激酶成红细胞原癌基因B2(ERBB2),也称为人表皮生长因子受体2(HER2),是一种致癌驱动基因,已成功应用在乳腺癌和胃癌的靶向治疗中。最近,下一代测序(NGS)发现ERBB2是转移性结直肠癌(mCRC)的一个有前景的治疗靶点,有 3-5% 的患者检出HER2变异,但目前还没有批准用于此用途的治疗方法。本文介绍了NGS检测...
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.
(BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act...